Atlas Venture inked corporate strategic partnership agreements with Amgen Inc., of Thousand Oaks, Calif., through its venture capital fund, Amgen Ventures, and Novartis AG, of Basel, Switzerland
Pearl reported Phase IIb results in 2011 that showed a statistically significant improvement in FEV1 of 47 percent over Foradil (formoterol, Novartis AG) and 49 percent over Spiriva (tiotroprium, Pfizer Inc./Boehringer Ingelheim GmbH) after one week of dosing (p < 0.0001 for both comparisons
By Catherine Shaffer | BioWorld Today | Wednesday, May 15, 2013
They include Tudorza Pressair (aclidinium bromide inhalation powder, Forest Laboratories Inc. and Almirall SA), given the FDA's nod last summer, and Arcapta Neohaler (indacaterol maleate, Novartis AG), approved in 2011
By Randy Osborne | BioWorld Today | Monday, May 13, 2013
Novartis Pharmaceuticals Corp., of East Hanover, N.J., part of Novartis AG, said the FDA approved the anti-interleukin antibody Ilaris (canakinumab) to treat active systemic juvenile idiopathic arthritis (SJIA) in patients 2 years and older
Array BioPharma Inc., a biotech known for its drug discovery engine, is expanding its capabilities, starting its first Phase III clinical trial for MEK 162. (See BioWorld Today, May 8, 2013.) As part of its partnership with Novartis AG to develop the MEK inhibitor, Array retained co-development rights, which allows it to run clinical trials to further the development of the compound
By Brian Orelli | BioWorld Insight | Monday, May 13, 2013
The findings appeared in the May 8, 2013, issue of Cell Metabolism. (See BioWorld Today, March 27, 2013.) Cancer Drug Fights Neurodegeneration Very low doses of chronic myelogenous leukemia (CML) drug Tasigna (nilotinib, Novartis AG) may be a way to treat neurodegenerative disorders that are characterized by toxic protein accumulations, scientists from Georgetown University have discovered
Its lead program, RPC1063, is a sphingosine 1-phosphate receptor (S1PC) modulater that the company hopes will be competitive with Gilenya (fingolimod), the oral MS drug sold by Novartis AG
By Catherine Shaffer | BioWorld Today | Friday, May 10, 2013
Oxford BioMedica plc, of Oxford, UK, signed an agreement with Novartis AG, of Basel, Switzerland, to manufacture clinical grade material using Oxford BioMedica's LentiVector gene delivery technology and to provide certain process development services
Array BioPharma Inc.'s Phase III trial planned for this summer in recurrent low-grade serous ovarian cancer (LGSOC) with its Novartis AG-partnered MEK inhibitor is one of a handful of late-stage studies expected to roll out this year
By Randy Osborne | BioWorld Today | Wednesday, May 8, 2013
BIO said it shares many of the USTR's concerns over the decision by India's Supreme Court to deny patent protection for for the cancer drug Gleevec/Glivec, developed by Novartis AG, of Basel, Switzerland, on the grounds that the compound did not demonstrate "enhanced efficacy
Novartis AG (Basel, Switzerland) $25 For the start of a Phase II trial testing c-MET inhibitor INC280 as monotherapy in patients with advanced hepatocellular carcinoma 4/30/13 Isis Pharmaceuticals Inc. (Carlsbad, Calif.) Biogen Idec Inc. (Weston, Mass.) $3.5 For the start of a Phase II study of ISIS-SMNRx in infants with spinal muscular atrophy
Oxford BioMedica plc, of Oxford, UK, signed an agreement with Novartis AG, of Basel, Switzerland, to manufacture clinical grade material using Oxford BioMedica's LentiVector gene delivery technology and to provide certain process development services
At the start of the session, MacDougall described two success stories emerging from previous pitch competition panels over the years, including one firm that ended up inking a deal with Novartis AG
Novartis Pharmaceuticals Corp., of East Hanover, N.J., part of Novartis AG, said it disputes the allegations made by the U.S. Attorney's Office for the Southern District of New York in two complaints filed
Incyte Corp., of Wilmington, Del., said it earned a $25 million milestone payment from Novartis AG, of Basel, Switzerland, based on the start of a Phase II trial testing c-MET inhibitor INC280 (formerly INCB28060) as monotherapy in patients with advanced hepatocellular carcinoma
Among the pharma companies, the report found that Novartis AG, of Basel, Switzerland, will maintain its position as the world's top orphan drug company in 2018, with expected sales of $11.8 billion
By Peter Winter | BioWorld Insight | Monday, April 29, 2013
